scholarly journals Knowledge on Breast Cancer among College Students

2021 ◽  
Vol 01 (01) ◽  
pp. 19-23
Author(s):  
Suresh M ◽  
◽  
Anchal Yadav ◽  
Keyword(s):  
Breast Cancer ◽  
College Students ◽  
Survival Rates ◽  
Target Population ◽  
Female Students ◽  
Breast Cancers ◽  
Adequate Knowledge ◽  
Inadequate Knowledge ◽  
Incidence And Mortality ◽  
Early Case

Background: Globally, breast cancer is one of the most common cancer among females of age group 15-40 years. India is also one of the leading countries of breast cancer. It is found that incidence rate of breast cancer is higher in less developing countries in comparison to development country. In 2018, worldwide, nearly 2 million new breast cancer cases were diagnosed. Early diagnosis of breast cancer can increase the chance of early case detection and favourable outcomes, resulting in improved survival rates and quality of life of women and is therefore important public health strategy at all settings [2]. Several studies suggests that even though the incidence and mortality of breast cancer have been on the increase, the knowledge and awareness regarding the breast cancer is low among college students. Therefore, this study was conducted to assess knowledge and awareness among college students about breast cancers in Lucknow Materials & Methods: Descriptive research design was selected for this study. Target population includes the female students studying in the selected colleges of Lucknow. 87 female students were selected through non-probability, purposive sampling techniques. Data was gathered using a self-administered semi structured questionnaire. Results: Overall results of this study show that, 34 (39.08%) female students had adequate knowledge, 49 (56.32%) female students had moderately inadequate knowledge, and 04 (4.59%) female students had inadequate knowledge. Conclusion: Findings of this study revealed that knowledge of breast cancer among female college students was inadequate.

scholarly journals Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dechuang Jiao ◽  
Jingyang Zhang ◽  
Jiujun Zhu ◽  
Xuhui Guo ◽  
Yue Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cox Model ◽  
Survival Rates ◽  
Tumor Grade ◽  
Population Based ◽  
Rank Test ◽  
Breast Cancers ◽  
Significant Independent Predictor ◽  
Cancer Specific Survival ◽  
7Th Edition

Abstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Methods Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. Results Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). Conclusions Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients.

scholarly journals Effectiveness of Educational Intervention Programme on Knowledge Regarding Breast Self Examination Among Higher Secondary School Girls of Biratnagar

2017 ◽  
Vol 1 (1) ◽  
pp. 13-19 ◽  
Author(s):  
D. Sapkota ◽  
P. Parajuli ◽  
T.K. Kafle
Keyword(s):  
Breast Cancer ◽  
Secondary School ◽  
Educational Intervention ◽  
Knowledge Score ◽  
Breast Cancers ◽  
Intervention Programme ◽  
Breast Self Examination ◽  
Adequate Knowledge ◽  
Post Test ◽  
Self Examination

Introduction Breast self-examination (BSE) is a self-generated, non-invasive and non-irradiative method of breast cancer detection. Self examination of the breasts each month after the menstrual cycle is the simplest yet extremely important way to detect early breast cancer. It has been observed that women can detect 95% of breast cancers and 65% of early minimal breast cancers themselves. This method is harmless, less time consuming and can be performed by any woman.Objective To assess the effectiveness of educational intervention programme regarding Breast Self Examination among girl students of study school.Methodology Pre experimental one group pre-test post-test design was adopted for this study. In total, 61 girls were included. The result were analysed by using both descriptive as well as inferential statistics.Results In pre-test 75.4% had inadequate and only 1.6% had adequate knowledge regarding Breast Self Examination, in contrast, after the intervention the adequate knowledge was increased to 62.3%. The overall mean score was increased from 33.07% to 85.14%. The test of significance revealed that the increment in BSE knowledge score due to program intervention was highly significant (P< 0.001).Conclusion The educational intervention programme on BSE was found to be highly effective as the knowledge score was significantly increased after intervention of the package among higher secondary school girls.Birat Journal of Health Sciences 2016 1(1): 13-19

scholarly journals Breast Cancer Survival in the Mammography Era in Brazil: A Population-Based Analysis of 2,715 Cases

2021 ◽  
Author(s):  
Juliana Fernandes ◽  
Beatriz Machado ◽  
Cassio Cardoso-Filho ◽  
Juliana Nativio ◽  
Cesar Cabello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Population Based ◽  
Breast Cancer Survival ◽  
Stage I ◽  
Current Status ◽  
Breast Cancers ◽  
Risk Of Death ◽  
Significant Difference

Abstract Background This study aims to assess breast cancer survival rates after one decade of mammography in a large urban area of Brazil. Methods It is a population-based retrospective cohort of women with breast cancer in Campinas, São Paulo, from 2010 to 2014. Age, vital status and stage were accessed through the cancer and mortality registry, and patients records. Statistics used Kaplan-Meier, log-rank and Cox's regression. Results Out of the 2,715 cases, 665 deaths (24.5%) were confirmed until early 2020. The mean age at diagnosis was 58.6 years. Women 50-69 years were 48.0%, and stage I the most frequent (25.0%). The overall mean survival was 8.4 years (8.2-8.5). The 5-year survival (5yOS) for overall, 40-49, 50-59, 60-69, 70-79 years was respectively 80.5%, 87.7%, 83.7%, 83.8% and 75.5%. The 5yOS for stages 0, I, II, III and IV was 95.2%, 92.6%, 89.4%, 71.1% and 47.1%. There was no significant difference in survival in stage I or II (p=0.058). Compared to women 50-59 years, death's risk was 2.3 times higher for women 70-79 years and 26% lower for women 40-49 years. Concerning stage I, the risk of death was 1.5, 4.1 and 8.6 times higher, and 34% lower, respectively, for stage II, III, IV and 0. Conclusions In Brazil, breast cancers are currently diagnosed in the early stages, although advanced cases persist. Survival rates may reflect improvements in screening, early detection and treatment. The results can reflect the current status of other regions or countries with similar health care conditions.

Potential Use of Biomarkers to Augment Clinical Decisions for the Early Detection of Breast Cancer

2014 ◽  
Vol 10 (02) ◽  
pp. 103 ◽  
Author(s):  
Alan B Hollingsworth ◽  
David E Reese ◽  
◽  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Survival Rates ◽  
High Sensitivity ◽  
Standard Of Care ◽  
Serum Biomarkers ◽  
Breast Cancer Detection ◽  
Breast Cancers

Breast cancer remains a significant worldwide health problem, despite the fact that early detection is associated with excellent survival rates. Currently, a substantial proportion of breast cancers are not detected using routine screening. Therefore, there is a need to identify a technology that can improve the precision and accuracy of early breast cancer detection. Biomarkers are attractive in that they can potentially detect early cancers with high sensitivity, while distinguishing between benign disease and invasive cancers. Many commonly used serum biomarkers have limited use in screening assays for breast cancer as single agents due to the heterogeneous nature of breast cancer. However, the use of protein panels that detect multiple serum biomarkers offer the potential for enhanced sensitivity and specificity in a clinical setting. Recently, a serum biomarker test comprising five serum biomarkers for breast cancer was clinically validated and showed high sensitivity and specificity. Additional panels have been developed that combine serum protein biomarkers (SPB) and tumor-associated autoantibodies (TAb) to further enhance the clinical utility of the assay. Serum biomarkers are currently not the standard of care and are not recommended in any detection guidelines. However, tumor biomarkers are used in the breast cancer setting to determine the course of care. The purpose of this article is to review recent advances in SPB, TAb, and biomarkers used in breast cancer detection to provide a perspective on how these technologies may offer benefit when combined with current imaging modalities.

Breast cancers with stem cell-like features delineate endocrine responsiveness

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 10517-10517
Author(s):  
A. Rody ◽  
T. Karn ◽  
C. Solbach ◽  
R. Gaetje ◽  
R. Diallo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Lymph Node ◽  
Survival Rates ◽  
Disease Recurrence ◽  
Normal Breast ◽  
Endocrine Treatment ◽  
Breast Cancers ◽  
Er Positive ◽  
Er Status

10517 Background: Endocrine responsiveness is one of the most important characteristics of breast cancer. The negative association between expression of the estrogen receptor (ER) and proliferation detected in normal breast is frequently lost in breast cancers leading to receptor independent growth and poor patients’ prognosis. Methods: Microarray analysis of 171 breast cancer samples allowed the discrimination of a KIT+ tumor group by using a set of genes coregulated with the “stem cell factor” receptor KIT. Validation was performed on three independent datasets encompassing 637 samples. Furthermore the response to endocrine treatment only was analyzed in a dataset of 700 patients. Results: KIT+ tumors are transcriptionally related to proposed mammary stem cells. Two types of KIT+ tumors were identified which are characterized by their positive and negative ER status, respectively. The inverse link of ER expression and proliferation is perfectly conserved within the KIT+ tumor groups, while it is uncoupled among half of the KIT-Low ER positive tumors. Those “uncoupled” ER positive tumors with altered ER response are characterized by a prognosis inferior to the ER negative cancers despite an apparent positive ER status (hazard ratio for disease recurrence, 2.07; 95% CI 1.53–2.81; P<0.001). Moreover, the 5 and 10 year survival rates of lymph node negative “uncoupled” tumors are even worse than those of lymph node positive “normal” ER positive cancers. While all ER positive patients seem to profit from endocrine treatment the relative benefit was reduced in uncoupled tumors (21.2 % vs. 31.7 %). Conclusions: The classification of breast cancers according to this biologically based model identified clinical relevant tumor groups whose further characterization will have important implications. Moreover, since the ability to recognize malfunctions in ER pathways largely depends on an appropriate reference system, the KIT+ tumors could allow a dissection of estrogen responsiveness giving crucial insights for prediction of response to endocrine therapy. No significant financial relationships to disclose.

scholarly journals Inflammatory breast cancer: Where are we now?

2003 ◽  
Vol 11 (3) ◽  
pp. 143-144
Author(s):  
Sladjana Filipovic
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Combined Modality Therapy ◽  
Survival Rates ◽  
Distant Metastases ◽  
Axillary Node ◽  
High Rate ◽  
Breast Cancers ◽  
Term Survival ◽  
Palpable Mass

Inflammatory breast cancer is perhaps the most aggressive form of breast neoplasm, with a poor prognosis. Clinically, inflammatory breast cancer is characterized by erythema and edema of the skin of the breast, called "peau d`orange", with or without an associated palpable mass. This form represents 1% to 6% (doubled during the past two decades) of all newly diagnosed breast malignancies and is often considered together with local advanced breast cancer, despite specific differential features. The reported 5-year survival rates range from 10% to 75%. On mammography, a diffuse increase in density and skin thickening may be present. Pathologic confirmation of invasion of dermal lymphatics by malignant cells can help distinguish this condition from benign mastitis. Most inflammatory breast cancers are on biopsy poorly differentiated ductal carcinomas, mainly estrogen and progesterone receptor negative. HER2/neu-overexpression and p53 gene mutations are frequently present. The probability of axillary node involvement is approximately 90%. Contralateral breast cancer develops in 25% to 50% of the patients, usually in the presence of metastases. Inflammatory breast cancer has a high rate of locoregional recurrence after surgery and/or radiotherapy and the rapid appearance of distant metastases. However, long-term survival is possible for these patients if treated with multimodality therapy including polychemotherapy, mastectomy, and loco-regional radiotherapy. The optimal sequencing of combined modality therapy has not been determined. Although not all patients are candidates for such a regimen (often due to progression during treatment), for those that complete all phases of therapy, more than one-third will be alive without disease at 10 years.

Postoperative Radiotherapy in N– Breast Cancer. A Retrospective Case-Control Study

1981 ◽  
Vol 67 (5) ◽  
pp. 443-445 ◽  
Author(s):  
Mario Cappellini ◽  
Stefano Ciatto ◽  
Raffaello Mungai
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Postoperative Radiotherapy ◽  
Survival Rates ◽  
Radical Mastectomy ◽  
Case Control ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Retrospective Case ◽  
Control Study

The role of postoperative radiotherapy in N- breast cancer with centrally or medially located tumors is still controversial. The authors report the results of a retrospective non-randomized case-control study of T1–2 N- breast cancer patients with centrally or medially located tumors, treated or not with postoperative radiotherapy after radical mastectomy. Sixty-four patients were treated with postoperative radiotherapy (Co-60) to the internal mammary chain and supraclavicular nodes. Sixty-four control cases, matched by T size and site, N status, age and menstrual status and simply followed-up after radical mastectomy were selected. No significant differences in actuarial recurrence and NED survival rates were observed at 5 years in the 2 compared groups, thus indicating that postoperative radiotherapy for patients with N- centrally or medially located breast cancers is not worthwhile treatment policy.

Synthesis and Clinical Development of Palbociclib: An overview

2020 ◽  
Vol 17 ◽  
Author(s):  
Debabrata Konar ◽  
Saurabh Maru ◽  
Subhabrata Kar ◽  
Kapil Kumar
Keyword(s):  
Breast Cancer ◽  
Acquired Resistance ◽  
Survival Rates ◽  
Metastatic Breast ◽  
The United States ◽  
Breast Cancers ◽  
Cancer Awareness ◽  
Primary Resistance ◽  
Awareness Campaigns ◽  
Active Research

: Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer. The past few years have seen a substantial increase in breast cancer awareness campaigns and active research in fields of diagnosis and targeted therapy. These factors have led to a better mechanistic understanding of the disease, detection at earlier stages and more personalized approach to treatment, ultimately causing a crucial increase in the survival rates after detection. However, with the advances in treatment, cases of patients developing primary resistance and acquired resistance are increasing. Most of the breast cancers which develop resistance to therapy are ER+ and are typically treated with tamoxifen and fulvestrant. These drugs either lower the levels of estrogen or inhibit the receptors for estrogen and prevent the tumor from spreading. Around one third of women treated with these drugs develop resistance to them, lowering their chances of survival. This has directed to the search of newer drug therapies to target advanced breast cancer and resistance. One of these efforts has resulted in the development of Palbociclib, a first in class inhibitor of cyclin dependent kinases 4 and 6 (CDK4 and CDK6), which was granted accelerated approval from FDA for combination therapy in postmenopausal women with ER+, HER2- metastatic breast cancer. This review is focused on the various aspects of “Palbociclib” including its synthesis, molecular modeling studies and efficacy and safety profile with clinical trials data.

scholarly journals RNA-Based TWIST1 Inhibition via Dendrimer Complex to Reduce Breast Cancer Cell Metastasis

2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
James Finlay ◽  
Cai M. Roberts ◽  
Gina Lowe ◽  
Joana Loeza ◽  
John J. Rossi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Target Genes ◽  
Epithelial Mesenchymal Transition ◽  
Survival Rates ◽  
The United States ◽  
Cellular Migration ◽  
Migration And Invasion ◽  
Breast Cancers ◽  
Mesenchymal Transition

Breast cancer is the leading cause of cancer-related deaths among women in the United States, and survival rates are lower for patients with metastases and/or triple-negative breast cancer (TNBC; ER, PR, and Her2 negative). Understanding the mechanisms of cancer metastasis is therefore crucial to identify new therapeutic targets and develop novel treatments to improve patient outcomes. A potential target is the TWIST1 transcription factor, which is often overexpressed in aggressive breast cancers and is a master regulator of cellular migration through epithelial-mesenchymal transition (EMT). Here, we demonstrate an siRNA-based TWIST1 silencing approach with delivery using a modified poly(amidoamine) (PAMAM) dendrimer. Our results demonstrate that SUM1315 TNBC cells efficiently take up PAMAM-siRNA complexes, leading to significant knockdown of TWIST1 and EMT-related target genes. Knockdown lasts up to one week after transfection and leads to a reduction in migration and invasion, as determined by wound healing and transwell assays. Furthermore, we demonstrate that PAMAM dendrimers can deliver siRNA to xenograft orthotopic tumors and siRNA remains in the tumor for at least four hours after treatment. These results suggest that further development of dendrimer-based delivery of siRNA for TWIST1 silencing may lead to a valuable adjunctive therapy for patients with TNBC.

scholarly journals Awareness of Breast Cancer and its Early Detection Measures among Female Students, Northern Ethiopia

2016 ◽  
Vol 5 (3) ◽  
pp. 213
Author(s):  
Tesfay Hailu ◽  
Hailemariam Berhe ◽  
Desta Hailu
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Early Detection ◽  
Sampling Technique ◽  
Knowledge Score ◽  
Female Students ◽  
Warning Signs ◽  
Northern Ethiopia ◽  
Breast Cancers ◽  
Cross Sectional

Globally breast cancer is the most common of all cancers. Since risk reduction strategies cannot eliminate the majority of breast cancers, early detection remains the cornerstone of breast cancer control. This paper, therefore, attempts to assess the awareness of breast cancer and its early detection measures among female students in Mekelle University, Ethiopia. An institution based cross-sectional study was conducted on randomly selected female students. Multistage sampling technique was employed to select the participants. A pre-tested structured questionnaire was used. Data analysis was carried out using SPSS version 16. In this study, 760 students participated making a response rate of 96 percent. Respondents with good knowledge score for risk factors, early detections measures and warning signs of breast cancer were 1.4 percent, 3.6 percent and 22.1 percent respectively. The majority 477 (62.8 percent) of participants practiced self-breast examination. In conclusion the participants had poor knowledge of risk factors, early detection measures and early warning signs of breast cancer.Therefore, the Ministry of health of Ethiopia together with its stalk holders should strengthen providing IEC targeting women to increase their awareness about breast cancer and its early detection measure.

Sign in / Sign up

Export Citation Format

Share Document